SOURCES SOUGHT
Q -- Measurement of Autoantibodies Against PFDN2
- Notice Date
- 7/1/2017
- Notice Type
- Sources Sought
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, Nat'l Institute of Diabetes, Digestive, & Kidney Diseases, 2 Democracy Plaza, Suite 700W, 6707 Democracy Blvd., MSC 5455, Bethesda, Maryland, 20892-5455
- ZIP Code
- 20892-5455
- Solicitation Number
- NICHD-17-125
- Archive Date
- 7/25/2017
- Point of Contact
- Verne Griffin,
- E-Mail Address
-
verne.griffin@nih.gov
(verne.griffin@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- This Small Business Sources Sought Notice is for information and planning purposes only and shall not be construed as a solicitation or as an obligation or commitment by the Government. This notice is intended strictly for Market Research. The National Institutes of Health (NIH) Eunice Kennedy Shriver, National Institute of Child Health and Human Development is conducting a market survey to determine the availability and technical capability of qualified small business, veteran-owned small business, service-disabled veteran-owned small business or HUBZone small businesses capable of providing Measurement of Autoantibodies Against PFDN2. The NIDDK in Phoenix performs research studies investigating the cause of obesity and diabetes. An important aspect of the development of type 2 diabetes mellitus may involve an immune response which leads to diminished insulin secretion and may involve production of autoantibodies. In particular, it has been observed that individuals without a particular HLA haplotype (HLA-DR2b) may be at higher risk for the development of diabetes because of an immune response that may decrease insulin secretion. In Phase 1, collected blood samples were screened on a protein microarray containing over 9000 unique proteins to identify possible candidate autoantibodies. Phase 2 involved screening plasma samples for antibodies to 77 candidate proteins based on evidence from Phase 1 and identified evidence of autoantibodies to 14 proteins. In Phase 3, the presence of autoantibodies to these 14 proteins were evaluated in a larger sample size and one autoantibody remained associated with type 2 diabetes in this larger cross-sectional study involving 900 samples. The intended procurement will be classified under North American Industrial Classification (NAICS) code 541711 with a size standard of 1000. All respondents are requested to identify their firm's size and type of business. Interested firms responding to this market survey must provide (a) capability statement demonstrating their experience, skills and capability to fulfill the Government's requirements for the above. The capability statement shall be in sufficient enough detail, but not to exceed 15 pages, so that the Government can determine the experience and capability of your firm to provide the requirements above. Your capability statement, not to exceed 15 pages, should include references. Capability statement must be received at the email address identified in this synopsis by 11:00 A.M. local time on July 10, 2017. Any questions regarding this announcement must be sent via email to verne.griffin@.nih.gov and must include solicitation NICHD17-125 in the subject line of email. This synopsis is for information and planning purposes and is not to be construed as a commitment by the Government, nor will the Government pay for information solicited. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provided feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate response to a solicitation. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provided feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate response to a solicitation. Confidentiality - No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s)." PLEASE NOTE: In order to receive an award, contractor must be registered and have valid certification in the System for Award Management (SAM) http://www.sam.gov
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDDKD/NICHD-17-125/listing.html)
- Record
- SN04566361-W 20170703/170701233153-749ab7c7b2838eeef9807d3814a09050 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |